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Abstract
Background De novo mutations in PURA have
recently been described to cause PURA syndrome, a
neurodevelopmental disorder characterised by severe
intellectual disability (ID), epilepsy, feeding difficulties
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and neonatal hypotonia.
end of article.
Objectives To delineate the clinical spectrum of PURA
syndrome and study genotype-phenotype correlations.
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startle response (44%), hypersomnolence (66%) and
hypothermia (35%). Epilepsy (54%) and gastrointestinal
(69%), ophthalmological (51%) and endocrine problems
(42%) were observed frequently. Computational analysis
of facial photographs showed subtle facial dysmorphism.
No strong genotype-phenotype correlation was identified
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individuals. The identification of one individual through
targeted Sanger sequencing points towards the clinical
recognisability of the syndrome. Genotype-phenotype
analysis showed no significant correlation between
mutation classes and disease severity.

Introduction

Deletions in the 5q31.2q31.3 region have been
reported to cause a syndrome comprising severe
developmental delay, profound hypotonia, feeding
difficulties, abnormal breathing pattern and
seizures.1–5 Within this region, haploinsufficiency of
the purine-rich element binding protein A (PURA)
has been suggested as responsible for the observed
neurodevelopmental features by narrowing the
region of overlap to three genes.4 Further evidence
for the essential role of PURA in development came
from two articles describing 15 individuals with
intellectual disability (ID) and de novo mutations in
PURA.6 7 The pathogenicity of mutations in PURA
was further supported by publication of a cohort
of six additional individuals with ID and de novo
mutations in PURA and two case reports.8–10
The functionality of PURA is dependent on three
PUR motifs, PUR I, PUR II and PUR III.11 12 The
ubiquitously expressed PURA protein, Pur-alpha,
has multiple regulatory functions in processes
such as DNA replication and transcription, mRNA
transport and DNA repair.12 13 Several studies
have shown that Pur-alpha has an important role
in neuronal development and differentiation.14 In
animal models, Pur-alpha is involved in postnatal
brain development.15 16 The Pur-alpha deficient
knockout mouse model has a severe neurological

Reijnders MRF, et al. J Med Genet 2018;55:104–113. doi:10.1136/jmedgenet-2017-104946

J Med Genet: first published as 10.1136/jmedgenet-2017-104946 on 2 November 2017. Downloaded from http://jmg.bmj.com/ on 1 August 2018 by guest. Protected by copyright.

Original article

Phenotypes

Methods
Identification of PURA syndrome individuals and collection of
clinical and mutational data

Whole exome sequencing (WES) was performed in individuals
with ID in either diagnostic (n=20) or research (n=10) settings
(online supplementary methods). In one individual, targeted
massively parallel sequencing (MPS) of a severe childhood
epilepsy gene panel was used, and in a second individual, clinically suspected to have PURA syndrome, PURA [NM_005859]
was investigated with targeted Sanger sequencing. Parental
samples were tested to assess de novo state. A questionnaire
with clinical and mutational details was completed by clinicians.
Written consent for publication of photographs was obtained
from legal guardians.

Evaluation of previously published cases

Twenty-two individuals with PURA mutations have been
described in four different publications.6–9 We used the same
questionnaire to collect clinical and mutation data from individuals (n=22) reported in the literature.

Computational analysis of facial photographs

To visualise the characteristic facial features of PURA syndrome
individuals, we generated a realistic, deidentified average based
on 34 photographs of individuals (in this paper presented and
previously published photographs) at different ages. A control
average was created from 301 age-matched, healthy individuals. We used a fully automated algorithm that (1) annotated a
constellation of 68 facial landmark points on the face, (2) created
an average face mesh and (3) warped faces of each individual
onto the average face mesh. The face averaging algorithm was
inspired by previous work18 19 and improved upon with better

deidentification of individuals (online supplementary methods).
Interpretation of the composite PURA face was performed by a
panel of five independent dysmorphologists.

Functional assessment of PURA mutations in structural
homology models

For homology modelling of mutations, the crystal structures
of the N-terminal PUR domain (PDB-ID: 3K44) and of the
C-terminal PUR domain (PDB-ID: 5FGO) from Drosophila melanogaster were used as template. Homology structures of human
PUR domains were calculated using the PHYRE2 program.20 In
the case of the C-terminal PUR domain, the sequences of two
repeat IIIs were merged into one peptide chain to allow for
modelling of the entire domain. The human homology models
showed high confidence scores and were used for in silico mutational analyses using the program Coot.21 All mutations identified in our cohort and previously published cohorts6–9 were
included. Variants in PURA reported in the Exome Aggregation
Consortium (ExAC) database22 were included as controls. Deletions, frameshift, non-sense and missense mutations were manually classified depending on the position, size and function of the
affected amino acids. Point mutations were in silico introduced
using the standard rotamer library of Coot and analysed for the
appearance of steric clashes or repulsive forces of side chains.
They were classified based on the orientation of mutated side
chains and on our knowledge of functionally important surface
regions. Figures were prepared using the program Pymol (www.
pymol.org).

Results
Identification of 32 individuals

We report 32 individuals with mutations in PURA (figure 1). All,
but two, were identified using WES in a diagnostic setting (individuals 1–10, 20–27, 30 and 32) or research setting (individuals
12–19, 29 and 31). Individual 28 was identified using targeted
MPS of a severe childhood epilepsy gene panel. Individual 11
was clinically suspected to have PURA syndrome based on postterm birth, severe neonatal hypotonia, hypersomnolence, exaggerated startle, persistent apnoeic episodes requiring continuous
SpO2 monitoring and supplementary oxygen, and feeding difficulties warranting nasogastric tube placement. Targeted Sanger
sequencing revealed a PURA mutation. Mutations were de
novo in 29 individuals. For the remaining three individuals, no
parental blood was available for testing. None of the individuals
had a second, likely pathogenic, genetic variant in WES data. All
identified missense mutations localised in one of the PUR repeat
sequences (figure 1).

Clinical delineation of 32 individuals

Clinical features observed in individuals reported in this
study are summarised in table 1. Numbers and percentages of
features were corrected for the number of individuals without
available information on a specific feature. More extensive and
detailed clinical information is available in online supplementary
table 1.

Gestation and neonatal problems

More than half (56%) of individuals were born after >41
weeks’ gestation. Induction of labour and/or caesarian
section were reported in 14 individuals. In 55% (6/11),
excessive hiccups were mentioned in utero. Neonatal problems were evident in all children immediately after birth.
Hypotonia was present in all but one of the neonates, often
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phenotype, including tremor and spontaneous seizures.16
Recently, heterozygous PURA knockout mice have been reported
to develop gait abnormalities, hypotonia and memory deficits.
Immunohistochemical assays displayed a reduced number of
neurons in cerebellum and hippocampus of these animals, which
is in line with their neurological, behavioural and cognitive
phenotypes.17
Mental
retardation,
autosomal
dominant
type
31[MIM616158], or ‘PURA syndrome’, the name of the
syndrome adopted by the parents and clinical community alike,
is phenotypically hallmarked by a wide spectrum of neurodevelopmental problems, including severe neurodevelopmental delay,
epilepsy, abnormal movements, hypotonia and brain abnormalities. Additionally, neonatal respiratory insufficiency and feeding
difficulties have been reported. Outside of this core phenotype,
a broad variability in clinical severity has been observed within
PURA syndrome.6–9 Different types of mutations have been identified so far and mutations occur throughout the gene. It has
been suggested that disruption of PUR repeat III possibly results
in a more severe phenotype, but additional studies are needed to
better understand the genotype-phenotype correlation of PURA
mutations.7
We present 32 individuals with de novo mutations in PURA.
With this large cohort, we delineate the clinical spectrum of
PURA syndrome. Computational modelling shows that subtle
overlapping facial dysmorphism is present. Additionally, we
present an approach for genotype-phenotype analysis of identified mutations and associated phenotypes, revealing that
observed phenotypic variability is probably not associated with
type and localisation of mutations.

Phenotypes

causing feeding difficulties (81%). Apnoeas and congenital
hypoventilation were reported in 48% of the neonates. Both
feeding and respiratory problems often required monitoring
in hospital: in 20 neonates, tube feeding, oxygen supplementation and/or mechanical ventilation were needed.
Hypersomnolence (66%) and hypothermia (37%) were
observed in a significant number of neonates. In about half
of the neonates (58%) an exaggerated startle response was
noted.

Development

All individuals with PURA mutations have moderate to severe
ID with severe language and motor delay. Most individuals
remain non-verbal (29/32, 91%), but many have better receptive language than expressive language and can follow simple
instructions. Severalnever achieved independent ambulation
(10/24 with age >5 years, 42%). For those who did, the age
of first steps ranged from 28 months to 7 years. Regression of
achieved skills due to the onset of seizures has been reported
in six individuals.
106

Neurological abnormalities
A variety of neurological problems were observed in individuals
with PURA mutations. Hypotonia, often more prominent in the
trunk, was present from birth. Spasticity of extremities at older
age was reported in three individuals, and Babinski response
was reported in another two. Gait, if achieved, was often
unstable and broad based. Stereotypic hand movements, in
some cases such as described for Rett syndrome [MIM312750],
were observed in several individuals (36%). Six out of 30
(20%) were mentioned to have a movement disorder, including
dystonia, chorea-like movements, seizure-like movements with
normal EEG and ataxic movements. Delayed myelination is the
most frequently reported brain abnormality observed on MRI
images (28%). Other, mostly a-specific, observed brain abnormalities (in 31% of individuals) include white matter abnormalities, prominent periventricular spaces, mild parenchymal
atrophy, widening of lateral ventricles and underdeveloped
rostrum of the corpus callosum. Peripheral neuropathy was
measured in five individuals at young age (online supplementary table 1).
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Figure 1 Localisation of PURA mutations and subdivision in classes. Mutations of individuals identified in our cohort are marked in bold. (A) Homology
models of N-terminal and C-terminal PUR domains (grey and blue, respectively) from human Pur-alpha. Residues with single amino acid exchanges are
depicted in red with side chains. (B) Location of reported PURA frameshift and non-sense mutations. Class A1 mutations are located in the N-terminal PUR
domain that affect both N-terminal and C-terminal domains and class A2 mutations occur in the C-terminal domain, affecting only this domain and the
C-terminus. (C) Identified point mutations in one of the PUR domains, predicted to cause local folding defects. (D) Four mutations of amino acids located on
the protein surface. Three mutations are predicted to affect nucleic acid binding (class C) and one mutation (class D) likely affects a surface-exposed residue,
which is not predicted to impair protein folding or nucleic acid binding. This mutation is possibly involved in not yet understood functions such as
protein–protein interactions. (E) Deletion (red) caused by mutation p.(Met1?) (class E), which disrupts the start codon. The protein is likely expressed from the
next in-frame start codon at amino acid 104, causing loss of a functional N-terminal PUR domain, but has an intact C-terminal PUR domain. (F) Localisation
of mutations reported in healthy controls in the ExAC database. All these mutations are predicted to have no effects on the folding and the function of the
Pur-alpha protein. PUR, purine-rich element.
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Literature (n=max 22)6–9

This article (n=max 32)
Clinical feature

Percentage (%)

Total (n=max 54)

Number

Percentage (%)

Number

Percentage (%)

Number

19

5/27

14

3/22

16

8/49

56

18/32

60

3/5

57

21/37

Growth
 Short stature (≤2.5 SD)
Pregnancy/delivery
 Gestational age >41 weeks
Neonatal problems
 Hypotonia

97

31/32

94

15/16

96

46/48

 Feeding difficulties

81

25/31

73

16/22

77

41/53

 GORD

28

8/29

17

1/6

26

9/35

 Breathing problems

48

15/31

68

15/22

57

30/53

 Hypersomnolence

66

19/29

NR

NR

66

19/29

 Hypothermia

37

10/27

25

1/4

35

11/31

 Excessive hiccups in utero

55

6/11

NR

NR

55

6/11

Neurological abnormality
 Moderate to severe ID
 Hypotonia

100

32/32

100

22/22

97

31/32

80

4/5

100

54/54

95

35/37

 Stereotypic hand movements

36

8/22

NR

NR

36

8/22

 Exaggerated startle response

58

11/19

27

4/15

44

15/34

 Epilepsy

50

16/32

59

13/22

54

29/54

 Delayed myelination

28

9/32

24

5/21

26

14/53

 Movement disorder

20

6/30

30

3/10

22

9/40

 Other brain abnormalities

31

10/32

29

6/21

30

16/53

Skeletal abnormality
 Scoliosis

28

9/32

18

2/11

26

11/43

 Hip dysplasia

23

7/31

0

0/11

17

7/42

 Hyperlaxity

43

9/21

9

1/11

31

10/32

Gastrointestinalabnormality
 Constipation

62

18/29

50

3/6

60

21/35

 Drooling

66

20/30

83

5/6

69

25/36

Respiratory abnormality

26

8/31

27

4/15

26

12/46

Cardiac abnormality

13

4/32

25

2/8

15

6/40

Urogenital abnormality

26

8/31

9

1/11

21

9/42

Ophthalmological abnormality

40

12/30

67

14/21

51

26/51

Endocrine abnormality
 Vitamin D deficiency

47

7/15

25

1/4

42

8/19

 Other

26

5/19

50

2/4

30

7/23

46

6/13

NR

NR

46

6/13

Skin abnormality
 Soft skin

GORD, gastro-oesophageal reflux disease; ID, intellectual disability; max, maximum; NR, not reported; PURA, purine-rich element binding protein A.

Half of the individuals (50%) were diagnosed with epilepsy. For
most of them, seizures started at the age of 2–4 years, but the age
of onset ranged from 6 months to 15 years. Different seizure types
were reported, including generalised tonic-clonic seizures, focal
seizures, absence seizures, epileptic spasms, tonic seizures, drop
attacks and over time, evolution to Lennox-Gastaut syndrome. The
epilepsy is often refractory to medical treatment and some individuals have never been seizure free. A longer follow-up period will be
required to determine the true prevalence of epilepsy, how refractory it is and what treatments are most effective.

Ophthalmological abnormalities

Eye abnormalities and visual problems were described frequently
in PURA syndrome individuals (40%). Strabismus (often
oesotropia) was the most commonly reported finding along with
strabismus-associated refractive errors (often hypermetropia).
Cortical visual impairment was reported in three individuals;

however, it is important to note that diagnostic criteria for
this condition are highly variable. One individual was treated
successfully for a congenital retinoblastoma. Nystagmus was also
described in a small number of cases (4/29; 14%) but details of
the phenotype are missing in reported cases.

Skeletal abnormalities

Progressive hip dysplasia and scoliosis were present in
respectively 23% and 28% of the cases and could possibly be
related to chronic truncal hypotonia (with or without abnormalities of limb tone), joint laxity and delayed or incomplete
motor development. Surgical correction was required in five
individuals in this cohort to date. The oldest individual was
18 years at time of surgery. Longer follow-up might show a
larger number of surgical interventions, since the majority
of included individuals (27/32) had an age of examination
below 18 years. Individuals showed a tendency to short

Reijnders MRF, et al. J Med Genet 2018;55:104–113. doi:10.1136/jmedgenet-2017-104946
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Table 1 Percentage of clinical features reported in individuals in this article (n=32) and meta-analysis with previously published PURA individuals
(n=22)6–9

Phenotypes

Gastrointestinal abnormalities

Due to severe hypotonia, swallowing problems and excessive
drooling were observed in more than half of the individuals
(66%). Constipation was often present (62%) and may be severe,
requiring the use of laxatives from early age.

Endocrine abnormalities

A diverse range of endocrine problems were reported, with low
vitamin D most commonly reported (47%), and less frequently
observed abnormalities including aberrant sex hormone levels,
abnormal cortisol response and aberrant thyroid hormone levels
(26%) (online supplementary table 1). It is likely that these problems are more common than observed, since not all individuals
have been tested for endocrine abnormalities.

Congenital structural malformations

Although not frequently reported, some individuals had congenital malformations of the heart, urogenital and/or respiratory
tract. Cardiac malformations included a ventricular septal defect
in two individuals, and an aberrant left subclavian artery, pulmonary stenosis and mild, spontaneously closed persistent ductus
arteriosus each in one individual. Abnormalities of the urogenital tract were described in five individuals: cryptorchidism in
three, kidney stones in two, and congenital hydronephrosis with
megaureter and urinary reflux each in one individual. Laryngeal
cleft was reported in a single case.

Facial dysmorphisms

Photographs of 21 individuals are shown in figure 2. No striking
similarities were observed, but a myopathic face, high anterior

hairline, almond-shaped palpebral fissures and full cheeks were
reported recurrently by clinicians. The presence of these features
was confirmed by a panel of five independent dysmorphologists,
all being asked to analyse photographs of PURA syndrome individuals from figure 2. They also mentioned eversion of lower
lateral eyelids, prominent, well-defined philtrum and retrognathia as features present in a subset of individuals.

Expansion of the cohort with 22 previously published cases

We structurally analysed mutational and clinical data of 22
previously published individuals.6–9 An overview of published
mutations is present in figure 1 and summarised clinical information is available in online supplementary table 2.

Recurrence of mutations

We found four recurrent mutations: p.(Lys97Glu) in individual
20 and subject #4 in Lalani et al6; p.(Phe271del) in individual
28 and subject #1 in Lalani et al6; p(Arg245Pro) in individuals
1 and 15; p.(Phe233del) in individuals 4, 5 and 14, patient 4
in Tanaka et al8 and patient 4 in Hunt et al.7 In addition, individuals 24 and 31 had two distinct mutations (c.153delA and
c.155delG, respectively) that were both predicted to give rise to
the same truncated protein product (p.(Leu54Cysfs*24)). There
were six individuals between whom two distinct missense mutations were identified at each of three different amino acid positions: p.(Leu100Arg) and p.(Leu100Pro) in individual 21 and
subject #1 in Lalani et al6; p.(Ile206del) and p.(Ile206Phe) in
individual 25 and patient 3 in Hunt et al7; p.(Val226Serfs*68)
and p.(Val226Glyfs*67) in individuals 6 and 10.

Clinical evaluation

Clinical features such as neurodevelopmental delay, epilepsy,
and brain and ophthalmological abnormalities have been
reported in all previously published cohorts. But for the majority
of features, no clinical information is available across all previously published cohorts. For example, hypersomnolence,

Figure 2 Photographs of 21 individuals with PURA mutations. Shared facial dysmorphism includes high anterior hairline, almond-shaped palpebral
fissures, full cheeks and hypotonic face. Strabismus is present in several of the PURA (purine-rich element binding protein A) individuals. Additionally,
independent dysmorphologists also observed eversion of lower lateral eyelids, prominent, well-defined philtrum and retrognathia in a subset of the
individuals.
108
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stature with five having a height ≤2.5 SD, and six others
with a height between −2 and −2.5 SD. From the remaining
16 individuals, only 2 had a height >0 SD. Low bone density
(z-score −4; 57%) was identified in a single case. Pes planus
was present in 11 individuals.

Phenotypes

stereotypic hand movements and excessive hiccups in utero have
not been reported in literature before. Using the summarised
clinical information (online supplementary table 2), we calculated the frequency of clinical features in all 54 individuals
(table 1).

Computational analysis of facial dysmorphism

Since no striking overlap in facial dysmorphism was observed,
but similarities between several individuals have been reported by
clinicians, we performed an objective computational analysis in
this paper presented and previously published photographs,
and compared it to the average image based on healthy controls
(figure 3). Ages at photographs ranged from 2 months to 19
years. A panel of five independent dysmorphologists agreed that
a myopathic face with typically open mouth appearance and full
cheeks was visible on the computational modelled PURA face.
Additionally, two dysmorphologists reported a slightly abnormal
shape of the eyes as (1) shorter palpebral fissures and (2) eversion of lower lateral eyelids. The high anterior hairline observed
in a subset of individuals (6,7,8,9,11,13,14,16,17,28) was not
visible on the computational model of the PURA face.

Modelling of all reported mutations into structural homology
models of human Pur-alpha

Using the previously reported crystal structures of the N-terminal and C-terminal PUR domains from the fruit fly D. melanogaster11 12 as templates, we generated structural homology
models for the corresponding domains of the human Pur-alpha
paralogue. Based on these homology-modelled structures, all 46
reported mutations were analysed and classified according to
their predicted effects on domain folding and function.
The identified frameshift and non-sense mutations affecting
the entire protein C-terminal to the site of mutation were
defined as class A mutations. Depending on whether mutations occurred in the N-terminal PUR domain and thus affect
N-terminal and C-terminal PUR domains or in the C-terminal
PUR only affecting this very domain plus C-terminus, we subclassified them as A1 and A2 mutations, respectively (figure 1B).

Mutations that were predicted to affect folding only locally, for
instance, via amino acid exchange of a buried residue or short
amino acid deletions in a folded region, were defined as class B
mutations (figure 1C). Since the RNA and DNA-binding mode of
Drosophila Pur-alpha has been structurally analysed,12 the human
homology model could also be used to predict mutations that
affect nucleic acid binding. Such mutations were found in four
individuals and were defined as class C mutations (figure 1D). We
also found one mutation likely affecting a surface-exposed residue
that was neither predicted to impair protein folding nor nucleic
acid binding. We suggest that this residue is involved in not yet
understood functions such as protein–protein interactions and we
defined this as class D mutation (figure 1D). Finally, we classified
one mutation as class E: p.(Met1?), causing loss of the start codon.
Translation is therefore likely to start at the next in-frame start
codon, which is located at protein position 104. As a result, the
protein will lack part of the N-terminal PUR domain, while it will
have an intact C-terminal PUR domain (figure 1E). As control, we
analysed variants reported by ExAC, a database containing variants of healthy controls (figure 1F). All of these variants resulted
in single amino acid exchanges that are either located outside the
globular domains or were exchanged against residues with similar
side chain properties. Variant p.(Gln136Pro) is the only exception
to this rule. It is located in the large loop region between repeats
I and II and thus likely allows to compensate the changes in backbone conformation upon mutation into proline.

Genotype-phenotype analysis

Remarkable clinical variability has been observed within the
total cohort of PURA syndrome individuals. To assess whether
this variability could be explained by the type and/or localisation of the identified mutations, we compared (1) phenotypes
of individuals with the same mutation and (2) phenotypes of
individuals with a mutation of the same class.

Recurrent mutations

We observed four recurrent mutations and two mutations with
a similar protein effect within the cohort, and compared their
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Figure 3 Computational analysis of photographs of PURA (purine-rich element binding protein A) syndrome individuals. Result of an objective
computational analysis on photographs of 34 individuals with PURA mutations (ages at photographs ranging from 2 months to 19 years; right image)
compared with the average image based on 301 age-matched, healthy controls (left image). The computational modelled PURA face showed a hypotonic
face with typically open mouth appearance and full cheeks. Additionally, two independent dysmorphologists reported a slightly abnormal shape of the eyes
as (1) shorter palpebral fissures and (2) eversion of lower lateral eyelids. The high anterior hairline observed in a subset of individuals is not visible on this
computational model of the PURA face.

Phenotypes
Recurrent PURA mutations and phenotype of affected individuals

Mutation

Individual/age

Reference

Phenotype

p.(Leu54Cysfs*24)

Individual 24
17 years

This article

Hypotonia, feeding difficulties requiring TF, GORD, apnoeas, hypersomnolence, hypothermia, severe ID, no
speech, walking at age 4 years, short stature (−5 SD), epilepsy, mild PDA, mild strabismus, scoliosis, hip
dysplasia, small hands and feet

Individual 31
16 years

This article

Hypotonia, feeding difficulties requiring TF, hypersomnolence, severe ID, no speech, not able to walk, short
stature (−2.75 SD), epilepsy, scoliosis, epilepsy, long fingers

Individual 20
2.5 years

This article

Hypotonia, mild feeding difficulties, hypersomnolence, no speech, not able to walk, mild constipation, pes
planus

Subject #4
21 months

Lalani et al6

Hypotonia, feeding difficulties, respiratory difficulties, seizures, ID, non-verbal, non-ambulatory, short stature
(1%), strabismus, duplex left kidney, hydronephrosis

Individual 4
14 years

This article

Hypotonia, feeding difficulties, apnoeas, hypersomnolence, severe ID, no speech, able to walk, ASD, stereotypic
hand movements, delayed myelination, swallow problems, severe hypermetropia, strabismus, low vitamin D,
low ferritin, pes planus, abnormal peripheral nerve testing

Individual 5
19 years

This article

Hypotonia, feeding difficulties, apnoeas, hypersomnolence, hypothermia, severe ID, no speech, not able to walk,
stereotypic hand movements, epilepsy, nystagmus, delayed myelination, drooling, constipation, strabismus, CVI,
scoliosis, hip dysplasia, low bone mineralisation, low vitamin D, anaemia, delayed puberty, small hands, pes
planus

Individual 14
9 years

This article

Hypotonia, severe ID, no speech, first steps age 7 years, epilepsy, delayed myelination, aberrant left subclavian
artery, VSD, drooling, refraction abnormality, strabismus, low vitamin D, high cholesterol

Patient 4
6 months

Tanaka et al8

Hypotonia, CVI, periventricular leukomalacia

Patient 4
6 years, 9 months

Hunt et al7

Hypotonia, feeding difficulties requiring TF, apnoeas, hypothermia, severe ID, not able to walk, essentially nonverbal, exaggerated startle response, dystonia, dyskinesia, epilepsy, CVI, delayed myelination, excessive extraaxial fluid spaces, cerebral atrophy, hyperprolactinaemia, blunted cortisol stress response, low vitamin D

Individual 1
19 years

This article

Hypotonia, feeding difficulties, severe ID, no speech, not able to walk, autistic-like traits, chorea-like
movements, Babinski response, delayed myelination, scoliosis, low vitamin D, hypogonadotropic hypogonadism

Individual 15
9 years

This article

Hypotonia, feeding difficulties requiring TF, apnoeas, hypersomnolence, hypothermia, severe ID, no speech, first
steps at age 4 years, epilepsy, drooling, constipation, pes planus

Individual 28
11 months

This article

Hypotonia, neonatal convulsions, moderate ID

Subject #1
6 months

Lalani et al6

Hypotonia, feeding difficulties, respiratory difficulties, seizures, ID, pedal oedema

p.(Lys97Glu)

p.(Phe233del)

p.(Arg245Pro)

p.(Phe271del)

ASD, autism spectrum disorder; CVI, cortical visual impairment; GORD, gastro-oesophageal reflux disease; ID, intellectual disability; PDA, persistent ductus arteriosus; TF, tube
feeding; VSD, ventricular septum defects.

phenotypes. For all mutations, remarkable differences between individuals with the same mutation were present (table 2). For example,
drug-resistant epilepsy was present in three out of five individuals
with mutation p.(Phe233del) and a cardiac abnormality in two out
of five individuals. The older of the two individuals without epilepsy
could walk, in contrast to the three individuals with epilepsy, who
were not able to walk or speak. For mutation p.(Leu54Cysfs*24),
individuals had more features in common, such as epilepsy, scoliosis
and short stature, but variation in ability to walk and heart abnormality was also observed.

Comparison of mutation classes

We compared phenotypes of individuals subdivided by mutation
class (online supplementary table 3). Overall, no significant differences in percentage of observed features between mutation classes
were present. One exception is mutation p.(Glu283Argfs*45),
which we classified as class D. This mutation affects only the very
C-terminus (all three PUR domains are intact) and it is unlikely that
this mutation interrupts protein folding or nucleic acid binding
(online supplementary table 4; figure 1). Clinical features in this
individual are less severe than observed in other individuals: the
14-year-old girl could walk independently from the age of 2 years
and could speak in sentences. Furthermore, no neonatal problems,
hypotonia, epilepsy or brain abnormalities were present.7 The clinical presentation of this girl is remarkably milder than other individuals, and could possibly be explained by the localisation of the
mutation at the C-terminus.
110

Discussion
We report 32 individuals with PURA syndrome, the largest
cohort so far. We systematically collected mutation and clinical
data on these and previously published individuals. With information on a total of 54 individuals, we were able to delineate the
clinical spectrum of this recently discovered syndrome.
The detailed and systematic collection of phenotypic data
allowed us to observe less frequently reported features related to
PURA syndrome. Clinical problems such as excessive hiccups in
utero (55% in our cohort), hypersomnolence (66% in our cohort),
stereotypic hand movements (36% in our cohort), regression
since onset of seizures (38% of individuals with epilepsy in our
cohort), soft skin (46% in our cohort) and short stature (19% in
our cohort) have not been reported before in published studies.
Post-term birth (56% in our cohort), gastro-oesophageal reflux
disease (28% in our cohort), hypothermia (37% in our cohort),
hypotonia after the neonatal period (97% in our cohort), constipation (62% in our cohort) and endocrine abnormalities (47%
in our cohort) only have been mentioned in one other study.
Similar to many other recently discovered novel syndromes for
which only a small subset of individuals have been described
initially, frequencies of features related to PURA syndrome were
difficult to estimate based on reported numbers. By expanding
the cohort, we were able to report a significant number of
features not formally associated with PURA syndrome before.
These features could be helpful for diagnosis and management
of PURA syndrome individuals.
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Table 2

Phenotypes
lab of the Radboudumc from 2013. Therefore, to more accurately
gauge the frequency within this population, a targeted re-evaluation
of all available exome data would be necessary.
In conclusion, we present a detailed overview of the clinical spectrum of PURA syndrome and a computational modelled PURA face,
which is essential for better recognition of this newly recognised
disorder and surveillance and management of symptoms after
initial diagnosis. Our suggested approach for genotype-phenotype
analysis by modelling of identified PURA mutations into human
homology models of experimentally determined crystal structures
from Drosophila Pur-alpha, showed that clinical variation observed
between individuals is probably not related to type and localisation
of mutations, but should be sought in other genetic and biological
mechanisms.
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The phenotype of PURA syndrome has been reported as difficult to recognise in daily clinical practice. Here, we show with the
identification of one individual using targeted Sanger sequencing in
a neonate, that it is possible to recognise PURA syndrome based
on clinical features. Severe neonatal problems including hypotonia,
respiratory and feeding difficulties, hypersomnolence and hypothermia, in the majority combined with post-term birth, could point
towards the early diagnosis of PURA syndrome. Although not a
consistent feature, the presence of myoclonic jerks in a neonate with
other features of PURA syndrome may be a useful feature to distinguish from Prader-Willi syndrome or peripheral neuromuscular
disorders such as spinal muscular atrophy (SMA). Known syndromes
such as congenital hypoventilation syndrome [MIM209880],
Prader-Willi syndrome [MIM176270], Rett syndrome, Angelman
syndrome [MIM160900], myotonic dystrophy [MIM160900] and
SMA [MIM253300] have been tested often in PURA syndrome
individuals. We recommend to considerPURA syndrome in the
differential diagnosis of any child tested for one or more of the
above syndromes, especially in the context of the aforementioned
neonatal problems and/or unexplained developmental delay.
After diagnosis of PURA syndrome, careful management of
existing medical problems and evaluation of health issues associated with PURA syndrome is essential. Our phenotypic overview
shows that different organ systems could be affected. Therefore, we
recommend routine care in a multidisciplinary team, with at least
a (child) neurologist, ophthalmologist, orthopaedic surgeon and
paediatrician for children aged below 18 years involved. Epilepsy,
present in half of the cohort, is a major problem. Some individuals have never been seizure free and regression of achieved developmental milestones since onset of seizures has been reported. In
future, studies focusing on epilepsy will be important to optimise
treatment of seizures related to PURA syndrome.
In general, individuals with epilepsy were more severely affected
than individuals without epilepsy. However, this explained only
partially the variation in developmental phenotypes observed
between individuals. To assess whether the clinical variability could
be related to the type and localisation of the identified mutations,
we performed a genotype-phenotype study by analysing recurrent
mutations and classifying mutations based on a homology model
derived from a crystal structure of the Drosophila PUR-alpha homologue. Interestingly, remarkable differences, such as the presence
or absence of epilepsy or congenital malformations, were observed
between individuals with the same mutation. For the remaining
mutations, class D mutations with localisation at the very end
of the C-terminus could possibly be correlated with a less severe
phenotype. But for the other mutations, phenotypic variability and
severity could not be related to the localisation and type of mutation.
Based on these results, we suggest that other genetic and biological
mechanisms contribute to the phenotypic variability. Further studies
are needed to obtain insight into these underlying pathological
mechanisms.
With the identification of 54 individuals within 2.5 years of the
initial description of the condition, PURA syndrome appears to be a
relatively frequent cause of ID. Previously, frequencies between 0.3%
and 0.5% in neurodevelopmental cohorts have been reported.6–8
Within our cohort, 10 individuals were identified in the diagnostic
lab facility of the Radboudumc, Nijmegen. These were found in a
total of 4700 individuals (~0.2%) with ID referred for WES. This
frequency is probably an underestimate. It has been reported that
PURA, a single-exon gene rich in guanine-cytosine content, could
be challenging to capture, similar to the first exon of multiexonic
genes.23 Furthermore, all 10 mutations have been identified after the
introduction of PURA as an ID gene in diagnostic gene panels at the
end of 2014, while WES had already been in use in the diagnostic
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